Drug Development Pipeline
ETD002 is a compound designed to increase the activity of TMEM16A, a chloride channel found on the surfaces of airway cells. Similar to the CFTR channel, the TMEM16A channel helps regulate the amount of salt and fluids on the airway surface. Increasing the activity of TMEM16A may help increase the amount of fluid within the airways to improve mucus clearance.
A phase 1 study to test the safety of ETD002 in healthy participants is underway.
This program is sponsored by Enterprise Therapeutics and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More